Cargando…

Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol

INTRODUCTION: There is emerging evidence for stratified glucose-lowering responses to certain oral medications for type 2 diabetes (T2D) by individual characteristics. The objective of this study was to test whether glycaemic response to representative treatments of dipeptidyl peptidase-4 inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeu, Rui Qian, Brandon, Rebecca, Jiang, Yannan, Griffiths, Dale, Smallman, Kate, Moffitt, Allan, Doherty, Glenn, Paul, Ryan, Harré Hindmarsh, Jennie, Merriman, Tony R, Macaskill-Smith, Kerry, Orr-Walker, Brandon, Murphy, Rinki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467516/ https://www.ncbi.nlm.nih.gov/pubmed/32873667 http://dx.doi.org/10.1136/bmjopen-2019-036518

Ejemplares similares

Stratified glucose-lowering response to vildagliptin and pioglitazone by obesity and hypertriglyceridemia in a randomized crossover trial
por: Brandon, Rebecca, et al.
Publicado: (2023)

Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
por: Kim, Jong Ho, et al.
Publicado: (2016)

Protective Effects of Vildagliptin against Pioglitazone-Induced Bone Loss in Type 2 Diabetic Rats
por: Eom, Young Sil, et al.
Publicado: (2016)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Effects of Vildagliptin Add-on Insulin Therapy on Nocturnal Glycemic Variations in Uncontrolled Type 2 Diabetes
por: Li, Feng-fei, et al.
Publicado: (2017)

Liquid Chromatographic Methods for the Determination of Vildagliptin in the Presence of its Synthetic Intermediate and the Simultaneous Determination of Pioglitazone Hydrochloride and Metformin Hydrochloride
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Effect of vildagliptin add-on treatment to metformin on plasma asymmetric dimethylarginine in type 2 diabetes mellitus patients
por: Cakirca, Mustafa, et al.
Publicado: (2014)

Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin
por: Saito, Daisuke, et al.
Publicado: (2017)

Cost effectiveness of vildagliptin versus glimepiride as add-on treatment to metformin for the treatment of diabetes mellitus type 2 patients in Greece
por: Kousoulakou, Hara, et al.
Publicado: (2017)

Associations Between Sugars Intakes and Urinary Sugars Excretion and Carbon Stable Isotope Ratios in Red Blood Cells as Biomarkers of Sugars Intake in a Predominantly Māori Population
por: Te Morenga, Lisa, et al.
Publicado: (2021)

Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017)

Surfing the Vildagliptin Tsunami
por: Balachandran, Karthik
Publicado: (2020)

Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan
por: Odawara, Masato, et al.
Publicado: (2016)

Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study
por: Chen, Yulong, et al.
Publicado: (2019)

Data on vildagliptin and vildagliptin plus metformin combination in type-2 diabetes mellitus management
por: Das, Sambit, et al.
Publicado: (2021)

Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares
por: Flynn, Tanya J, et al.
Publicado: (2015)

how_are_we_stranded_here: quick determination of RNA-Seq strandedness
por: Signal, Brandon, et al.
Publicado: (2022)

Effect of Vildagliptin on Hepatic Steatosis
por: Macauley, Mavin, et al.
Publicado: (2015)

Adverse drug effects observed with vildagliptin versus pioglitazone or rosiglitazone in the treatment of patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
por: Bundhun, Pravesh Kumar, et al.
Publicado: (2017)

Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study
por: Erande, Suhas, et al.
Publicado: (2023)

Mild acute pancreatitis with vildagliptin use
por: Saraogi, Ravikant, et al.
Publicado: (2012)

Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis
por: Wiciński, Michał, et al.
Publicado: (2020)

Association of the lipoprotein receptor-related protein 2 gene with gout and non-additive interaction with alcohol consumption
por: Rasheed, Humaira, et al.
Publicado: (2013)

Effect of a health literacy intervention trial on knowledge about cardiovascular disease medications among Indigenous peoples in Australia, Canada and New Zealand
por: Crengle, Sue, et al.
Publicado: (2018)

Evidence-Based Policing Is Here to Stay: Innovative Research, Meaningful Practice, and Global Reach
por: Piza, Eric L., et al.
Publicado: (2022)

Effects of Vildagliptin or Pioglitazone on Glycemic Variability and Oxidative Stress in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: A 16-Week, Randomised, Open Label, Pilot Study
por: Kim, Nam Hoon, et al.
Publicado: (2017)

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents
por: Li, Chun-Jun, et al.
Publicado: (2014)

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
por: Hirose, Takahisa, et al.
Publicado: (2015)

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent
por: Tang, Yun-Zhao, et al.
Publicado: (2015)

Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study
por: Zang, Li, et al.
Publicado: (2019)

Here and There
Publicado: (1898)

A case of vildagliptin-induced interstitial pneumonia
por: Kuse, Naoyuki, et al.
Publicado: (2016)

Physicochemical Properties and Methods of Analysis of Vildagliptin (Review)
por: Polyakova, E. B., et al.
Publicado: (2022)

Is It Worth It?
por: Card, W. I.
Publicado: (1979)

Cardiovascular disease medication health literacy among Indigenous peoples: design and protocol of an intervention trial in Indigenous primary care services
por: Crengle, Sue, et al.
Publicado: (2014)

Biomarkers of acute lung injury: worth their salt?
por: Proudfoot, Alastair G, et al.
Publicado: (2011)

Efficacy and safety of nateglinide plus vildagliptin combination therapy compared with switching to vildagliptin in type 2 diabetes patients inadequately controlled with nateglinide
por: Kudo‐Fujimaki, Kyoko, et al.
Publicado: (2013)

Bioequivalence Studies of New Generic Formulations of Vildagliptin and Fixed-Drug Combination of Vildagliptin and Metformin Versus Respective Originator Products in Healthy Volunteers
por: Schnaars, Yvonne, et al.
Publicado: (2022)

Cost Benefit Analysis of Sports Medicine Team Coverage: Is It Worth Our While?
por: Tjoumakaris, Fotios P., et al.
Publicado: (2013)

The Efficacy of Vildagliptin in Korean Patients with Type 2 Diabetes
por: Moon, Jun Sung, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4e2u4q3becs91qpbgrkg7bt9mf